other material
confidence high
sentiment positive
materiality 0.40
Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA
Phathom Pharmaceuticals, Inc.
- First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.
- Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.
- Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.
- Topline results from primary and secondary endpoints are anticipated in 2027.